Meet Sprout

At Sprout Pharmaceuticals, we’re endeavoring to breakthrough with the first FDA approved treatment for women’s most common sexual dysfunction. Based in Raleigh, NC, the company is focused solely on the delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder (HSDD), or distressing low sexual desire. Sprout is pursuing the FDA approval of flibanserin to treat HSDD in premenopausal women, for which there is currently no FDA-approved treatment.

Sit At Our Glass Table

Novel ideas fuel our entrepreneurial passion. Sit with us at our glass table, where we have lunch together daily, to get a taste of our culture. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we’re trying to collectively accomplish.

We’re On A Mission

Singular in our focus, our leadership team sold off a successful business in male sexual health to take on the pursuit of this much needed scientific and societal breakthrough for women. Led by a woman dedicated to this first for women, our CEO, Cindy Whitehead, and the work of the committed Sprout team has been featured on news outlets including ABC 20/20, Yahoo! News with Katie Couric, Good Morning America, Nightline, Huffington Post, and CBS This Morning.

We'd Love to Hear From You

Share your story (thank you to all the women and couples who already have!), your interest in joining us or your inquiries. We’d love to hear from you!

To Join Us, click here.

Learn Our Latest

Sprout Pharmaceuticals Names Cindy Whitehead CEO

Raleigh, N.C., January 6, 2015 – Sprout Pharmaceuticals today announced that Cindy Whitehead has been named CEO, effective immediately. Cindy co-founded Sprout Pharmaceuticals and previously served as president and chief operating officer. Former CEO Bob Whitehead...

Sprout Pharmaceuticals Receives Clear Guidance from FDA on Path Forward to Resubmit New Drug Application for Flibanserin, the First Potential Medical Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women

Agency Proposes Select Phase I Studies as Part of Resubmission Raleigh, N.C., February 11, 2014 – Sprout Pharmaceuticals announced today that their Formal Dispute Resolution, which was filed in December 2013, resulted in clear guidance from the FDA on the path...